Trial Search Results

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Forty Seven, Inc.

Intervention(s):

  • Drug: Hu5F9-G4

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Patients with histologically or cytologically confirmed advanced solid malignancy or
Lymphoma

Relapsed or refractory disease after at least 1 prior systemic treatment for the primary
malignancy and not a candidate for other curative treatment.

Adequate hematologic status

Adequate coagulation function

Adequate hepatic function

Adequate renal function

Exclusion Criteria:

Known primary tumors of central nervous system disease

Known active brain metastases

Known cardiopulmonary disease

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Olga Generalova
650-498-5188
Recruiting